$FUL

FULLER H B CO (FUL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex_989568.htm EXHIBIT 10.1 ex_989568.htm Exhibit 10.1 This AMENDMENT NO. 3, dated as of July 17, 2026 (this “ Amendment ”), is made and entered into by and among H.B. FULLER COMPANY, a Minnesota corporation (the “ Borrower ”), the Subsidiary Guarantors listed on the sig

Advanced Medical Solutions Group PLC (AMS) published the scheme document for a recommended cash acquisition of all AMS shares by Bidco, a wholly owned subsidiary of H.B. Fuller. The deal follows a possible offer announcement in May 2026 and requires court and shareholder approvals, with meetings set for 12 Aug 2026. The scheme is expected to become effective in Q3 or Q4 2026.

FULLER H B CO (FUL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 5 ex_981230.htm EXHIBIT 10.2 ex_981230.htm Exhibit 10.2 SECURED BRIDGE CREDIT AGREEMENT dated as of June 25, 2026, among H.B. FULLER COMPANY The Lenders Party Hereto and GOLDMAN SACHS BANK USA, as Administrative Agent GOLDMAN SACHS BANK USA, as Sole Lead Arranger and Book

FULLER H B CO (FUL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_980922.htm EXHIBIT 99.1 ex_980922.htm Worldwide Headquarters 1200 Willow Lake Boulevard St. Paul, Minnesota 55110-5101 Exhibit 99.1 Scott Jensen Investor Relations Contact investors@hbfuller.com NEWS June 24, 2026 H.B. Fuller Reports Second Quarter 2026 Results Repor

H.B. Fuller (NYSE: FUL) said it has made a recommended cash offer to acquire Advanced Medical Solutions Group plc (LSE: AMS). AMS shareholders would receive £2.85 per share, valuing the deal at £715 million. H.B. Fuller expects about $55 million run-rate synergies by 2031, AMS to add ~$300 million revenue, and a path to >20% EBITDA margin. The company targets deleveraging to 2.5x–3x within two years; closing is expected by year-end, subject to approvals.

Jefferies Financial Group bought 44,475 new shares of H. B. Fuller (NYSE: FUL) in Q4, worth about $2.64M, according to HoldingsChannel. Other institutions also increased stakes, including UBS and Cramer Rosenthal. FUL reported Q1 EPS of $0.57 (vs. $0.56) on revenue of $770.84M (vs. $787.77M) and declared a $0.245 quarterly dividend.

The article compares H. B. Fuller (NYSE:FUL) and AdvanSix (NYSE:ASIX) across dividends, valuation, earnings, risk, and ownership. FUL’s dividend is $0.98/share (1.7% yield) vs ASIX’s $0.64 (2.9%); FUL pays 32.3% of earnings vs ASIX 173%. FUL has beta 0.95 vs 1.33, and a $65.50 consensus price target vs $22.50.

H.B. Fuller Company (FUL) stock is experiencing a downturn due to a technical downgrade to Sell from StockInvest.us, following a 10% slide in recent sessions. This decline is exacerbated by sector-wide volatility in specialty chemicals, elevated options pricing, and weaker-than-expected first-quarter results with a revenue miss and a 7.2% drop in organic sales volumes. Weakness in construction and industrial markets further contributes to the bearish sentiment surrounding the stock.

Citigroup has raised its price target for H. B. Fuller (NYSE:FUL) to $70.00 from $67.00, affirming a "buy" rating on the specialty chemicals company's stock. This new target implies a potential upside of 17.19% from the current price. The article also details recent analyst ratings from other firms, H. B. Fuller's financial performance, and institutional holdings.

H.B. Fuller (FUL) recently reported Q1 2026 earnings with higher results on lower sales, leading to increased full-year revenue guidance and a 10% global price hike to combat inflation. This has led to a significant shift in sentiment, with the share price seeing a 20.04% return in 7 days, although it's still below the average analyst target. The article explores whether this presents a value opportunity or if future growth is already priced in, examining differing valuations from analysts and Simply Wall St's DCF model.